Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619364 | 0.81 | HPGDS (0.43) | HPGDSTRPV1 | |
| SCHEMBL19386405 | 0.78 | HPGDS (0.40) | HPGDSMAOBCYP3A4CYP2D6SLC6A2 | |
| SCHEMBL22446609 | 0.77 | TRPV1 (0.36) | TRPV1CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL19802020 | 0.77 | HPGDS (0.33) | HPGDSTRPV1 | |
| SCHEMBL26828848 | 0.74 | — | — | |
| SCHEMBL21497380 | 0.70 | GNRHR (0.41) | TRPV1KCNH2 | |
| SCHEMBL10078199 | 0.70 | LATS1 (0.39) | HPGDS | |
| SCHEMBL10249921 | 0.70 | KIF11 (0.38) | TRPV1 | |
| SCHEMBL24542822 | 0.70 | MAOB (0.36) | MAOB | |
| SCHEMBL20932780 | 0.69 | ALDH1A1 (0.39) | TRPV1MAOBCYP3A4CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | HPGDS 2524/4885TRPV1 796/4885MAOB 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.